This finding paralleled prior studies linking phosphatase gene mutations [e.g., PTPRD (47, 48)] to enhanced anti-tumor immunity, proposing PTPRT as a mechanistically relevant biomarker for guiding immunotherapy in BM. The gene discussed is PTPRT; the disease is neoplasm.